


Submitted by:  
Emily Costerison, Pharm.D.  
Managed Care Medical Communications, Medical Affairs  
Genentech, Inc.  
1 DNA Way  
South San Francisco, CA 94080  
Phone: (415) 509-2959  
Email: [genentechmedinfo-d@gene.com](mailto:genentechmedinfo-d@gene.com)  
Date of request: May 9, 2016  
NCCN Guidelines Panel: Breast Cancer

We kindly request the NCCN Breast Cancer Panel to consider adding clarifying information regarding preoperative HER2-targeted therapy to page BINV-12 [Preoperative Systemic Therapy: Surgical Treatment], as the guidelines have stated for endocrine therapy. Based on the current Guidelines, the Breast Cancer Panel recommends neoadjuvant HER2-targeted treatment for HER2-positive disease as an option prior to surgeries such as lumpectomy or mastectomy.

In the current guidelines, the potential benefits of preoperative HER2-targeted therapy for HER2-positive patients are elaborated in section BINV-L [Principles of Preoperative Systemic Therapy] and included as footnote "jj" on page BINV-12. At this critical time point of care before surgery, a clinician may overlook the footnote and the potential benefit of HER2 testing and the option of HER2-targeted therapy because neither are stated explicitly on page BINV-12.

As such, please consider the addition of explicit verbiage regarding the option of preoperative HER2-targeted therapy for HER2-positive patients alongside the consideration of endocrine therapy on page BINV-12. Specific language will make this information more consistent with the level of detail that presents endocrine therapy and will help clinicians be more informed of beneficial treatment options prior to surgery.

Respectfully submitted,



Emily Costerison, Pharm.D.

C#16-M0032